STAT

Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results

In a Q&A, Recursion’s incoming CEO acknowledges hype around the idea of using AI to expedite drug development, and says it's ...
STAT

Recursion seeks to deliver results, and a VC sees a wave of M&A coming

This week, my colleagues and I scheduled 30 minutes to talk with Mark Cuban for “The Readout LOUD” podcast. The conversation ...

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off. Plus: Stop Hiding Your Wins

Welcome to this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, ...

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?

Few would place Recursion Pharmaceuticals (NASDAQ: RXRX), a little-known biotech company, in the same league as these tech ...
Harvard Business Review

What’s Your Data Strategy?

The key is to balance offense and defense. by Leandro DalleMule and Thomas H. Davenport More than ever, the ability to manage torrents of data is critical to a company’s success. But even with the ...
Barron's

Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...